Safety and efficacy of sitagliptin in combination with transient continuous subcutaneous insulin infusion (CSII) therapy in patients with newly diagnosed type 2 diabetes

Comparison of the Effects of Continuous Subcutaneous Insulin Infusion and Add-On Therapy with Sitagliptin in Patients with Newly Diagnosed Type 2 Diabetes Mellitus

“…In our study, SUIT and CPI were used to assess β -cell responsiveness. Similar to the results of Yuan et al's study [ 22 ], the indicators of β -cell function, SUIT and CPI, were increased. These improvements were most likely due to the improvement of glycemic control in the CSII + Sig group compared with the CSII group.…”

“…Although an improvement in glycemic control using the combination of a DPP-4 inhibitor and insulin was demonstrated in previous studies [ 19 – 21 ], the intervention time in those studies was longer than 3 months. In patients with T2DM receiving CSII with add-on sitagliptin for 2 weeks, HbA1c was also significantly decreased compared with that in patients receiving CSII alone in a study by Yuan et al [ 22 ] However, HbA1c is an indicator of glycemic control over a 3-month period. In our study, GA was used to monitor the glycemic control state, as it is an indicator of glycation, over a 2-3 week period in diabetic patients.…”

“…Moreover, in previous clinical studies using concomitant therapy of insulin and sitagliptin, the effect of add-on sitagliptin on improving β -cell function was investigated in long-term interventions of at least 12 weeks [ 19 – 21 ]. In a study by Yuan et al [ 22 ], the levels of insulin and C-peptide were strikingly increased and HOMA- β (the homeostasis model assessment of β -cell function) was improved in the CSII plus sitagliptin group compared with the CSII group. In our study, SUIT and CPI were used to assess β -cell responsiveness.…”

Insulin pump in type 2 diabetes: B-cell focused treatment

“…Několik prací ukázalo, že sitagliptin v kombinaci s CSII vede k lepší kompenzaci DM2T u nově diagnostikovaných pacientů než CSII samotná. Na kombinační, byť jen krátkodobé, léčbě CSII + sitagliptin dochází ke zlepšení glykemie nalačno, glykemické variability, zvýšení citlivosti na inzulin a zvýšení hladin C-peptidu po stimulaci glukózou [23][24][25].…”

Improvement of β-cell function ameliorated glycemic variability in patients with newly diagnosed type 2 diabetes after short-term continuous subcutaneous insulin infusion or in combination with sitagliptin treatment: a randomized control trial

“…For each participant, we determined GV with capillary blood glucose CV during the first and second weeks of treatment. CV was calculated for both the first and second week of treatment for each participant by using the formula CV = (SD/M), where the M is the mean of capillary blood anced diet (60% carbohydrate, 15% protein, and 25% fat of the total energy value) was prescribed to all participants; total energy value was calculated based on relative metabolic rate (RMR) and physical activity, as follows: RMR × physical activity -(500 -1000 kcal/ day); the training program consisted of 40 minute aerobic exercise, such as walking, three times a week (on alternate days), at 70% of heart rate reserve [24]. The treatment objective for each group was the same, to achieve fasting and non-fasting capillary blood glucose levels of 4.4 to 6.0 mmol/L and less than 8.0 mmol/L, respectively, while avoiding clinical hypoglycemia.…”